N6-Methyladenosine RNA Methylation Correlates with Immune Microenvironment and Immunotherapy Response of Melanoma

The study examined the role of N6-methyladenosine (m6A) RNA methylation in melanoma, analyzing 1,564 patients across eight cohorts. It identified two m6A modification patterns, with low m6Ascores linked to an immune-inflamed phenotype and a 61.1% 5-year survival rate, while high m6Ascores were associated with an immune-excluded phenotype and a 52.2% survival rate. Low m6Ascores were also associated with better responses to anti-PD-1 and anti-CTLA4 therapies, with 90% of these patients responding to treatment. The study concluded that m6Ascore could be a valuable tool for predicting prognosis and guiding immunotherapy in melanoma patients.